Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Coya Therapeutics, Inc. ( (COYA) ) just unveiled an announcement.
On January 20, 2026, Coya Therapeutics, Inc. informed stockholders that its unaudited cash balance as of December 31, 2025 stood at $46.8 million, providing a projected cash runway into the second half of 2027 and supporting continued operations and development activities. The company also noted that it expects to deliver topline data from its ongoing ALSTARS Phase 2 trial in the first quarter of 2027, a milestone that could be pivotal for its clinical progress and of particular interest to investors and other stakeholders tracking its ALS program.
The most recent analyst rating on (COYA) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Coya Therapeutics, Inc. stock, see the COYA Stock Forecast page.
Spark’s Take on COYA Stock
According to Spark, TipRanks’ AI Analyst, COYA is a Neutral.
The score is primarily held back by weak financial performance (ongoing losses and very large TTM cash burn) and bearish technicals (below major moving averages with negative MACD). Offsetting these are supportive corporate developments (clinical progress, milestone payment, and extended cash runway), while valuation remains hard to assess due to negative earnings and no dividend.
To see Spark’s full report on COYA stock, click here.
More about Coya Therapeutics, Inc.
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative and other serious diseases, with a particular emphasis on advancing its ALSTARS Phase 2 program in amyotrophic lateral sclerosis (ALS).
Average Trading Volume: 263,226
Technical Sentiment Signal: Sell
Current Market Cap: $89.56M
See more insights into COYA stock on TipRanks’ Stock Analysis page.